OOIR: Observatory of International Research

Papers

(The H4-Index of Vaccine is 53. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Syncope after live attenuated influenza vaccine: Reports to the Vaccine Adverse Event Reporting System (2003–2024)	213
Editorial Board/Aims and Scope	201
Sublingual immunisation with GBS serotype III capsular polysaccharide-tetanus toxoid conjugate vaccine induces systemic and mucosal antibody responses which are opsonophagocytic and inhibit GBS coloni	172
Editorial Board/Aims and Scope	151
Managing multiplicity in clinical vaccine studies – A case study using a gatekeeping testing strategy	148
Editorial Board/Aims and Scope	132
Tackling the burden of mumps in the military: A report of the Defense Health Board	130
Humoral and cellular immune responses induced by serogroup W135 meningococcal conjugate and polysaccharide vaccines	115
TAK − 021, an inactivated Enterovirus 71 vaccine candidate, provides cross-protection against heterologous sub-genogroups in human scavenger receptor B2 transgenic mice	114
Issues with infectious disease vaccine introduction into routine vaccination in Japan, and considerations for accelerating the process	106
Pediatric otitis media in Japan: A nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010	102
A randomized, blind, parallel controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of 23-valent pneumococcal polysaccharide vaccine in healthy people aged 2 years an	95
COVID-19 vaccination communication: Effects of vaccine conspiracy beliefs and message framing among black and white participants	95
Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination	91
Characteristics of reported mumps cases in the United States: 2018–2023	91
Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study	91
“Every interaction you have …should be an opportunity to discuss and offer influenza vaccination”. Health service perspectives on influenza vaccination promotion and delivery to Aboriginal families li	90
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys	88
Editorial Board/Aims and Scope	81
Molecular engineering of a cryptic epitope in Spike RBD improves manufacturability and neutralizing breadth against SARS-CoV-2 variants	80
Corrigendum to ‘Cross-protective efficacy of inactivated whole influenza vaccines against Korean Y280 and Y439 lineage H9N2 viruses in mice’ [Vaccine 39 (2021) 6213–6220]	79
Erratum to “Motivational interviewing and vaccine acceptance in children: The MOTIVE study” [Vaccine 40(12) (2022) 1846–1854]	79
Erratum to “Quadrivalent HPV vaccine effectiveness against anogenital warts: A registry-based study of 2,2 million individuals” [Vaccine 41(37) (2023) 5469-5476]	78
Corrigendum to “Genotype prevalence and age distribution of human papillomavirus from infection to cervical cancer in Japanese women: A systematic review and meta-analysis” [Vaccine 40(41) (2022) 5971	76
Cost-effectiveness of anti-viral treatment for infants with RSV disease in the United Kingdom	75

Evaluation of dynamics of immune responses and protective efficacy in piglets immunized with an inactivated porcine reproductive and respiratory syndrome vaccine candidate	74
Humoral immune response profile of a cattle herd vaccinated with 5- and 10-times Bakirköy strain sheep pox vaccine under field conditions	74
Moderate effectiveness of influenza vaccine in outpatient settings: A test-negative study in Beijing, China, 2023/24 season	73
Effectiveness of the varicella vaccine in the real world, a matched case-control study	71
Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study	70
Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database	70
Long-term impact of rotavirus vaccination on all-cause and rotavirus-specific gastroenteritis and strain distribution in Central Kenya: An 11-year interrupted time-series analysis	69
Stability studies for the identification of critical process parameters for a pharmaceutical production of the Orf virus	68
The projected cost-effectiveness and budget impact of HPV vaccine introduction in Ghana	68
UK healthcare professionals’ attitudes towards the introduction of varicella vaccine into the routine childhood vaccination schedule and their preferences for administration	68
Compliance, procrastination and refusal: American COVID-19 vaccination trust and value orientation	68
Evaluating concurrency and gaps between self-report and vaccine card data for COVID-19 vaccination	67
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea	66
Cost-effectiveness of high-dose influenza vaccination in the Netherlands: Incorporating the impact on both respiratory and cardiovascular hospitalizations	65
Using the precaution adoption process model to understand decision-making about the COVID-19 booster vaccine in England	63
Vaccination during febrile illness, what do we know? A systematic-narrative hybrid review of the literature and international recommendations	62
Letter to the editor: SARS-CoV-2 vaccination in children and adolescents with neurodevelopmental or psychiatric disorders	59
A universal live vaccine platform against multiple serotypes Streptococcus suis based on polyvalent antigen protein	59
Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines	59
Supply, then demand? Health expenditure, political leanings, cost obstacles to care, and vaccine hesitancy predict state-level COVID-19 vaccination rates	58
Vaccination coverage in hematological patients undergoing chemotherapy: Should we move towards personalized vaccination?	58
Adjuvant-dependent impacts on vaccine-induced humoral responses and protection in preclinical models of nasal and genital colonization by pathogenic Neisseria	57
Effect of reduced two-dose (1+1) schedule of 10 and 13-valent pneumococcal conjugate vaccines (SynflorixTM and Prevenar13TM)) on nasopharyngeal carriage and serotype-specific immune response in the fi	57
Retesting the hypothesis that early Diphtheria-Tetanus-Pertussis vaccination increases female mortality: An observational study within a randomised trial	56
Nationwide rollout of HPV vaccination in Nepal: Early key insights	55
Vaccine financing in the Middle East and Africa: An overview from 2010 to 2019	55
Cost-effectiveness of human papillomavirus vaccination in girls living in Latin American countries: A systematic review and meta-analysis	54
Intranasal administration of a live-attenuated recombinant newcastle disease virus expressing the SARS-CoV-2 Spike protein induces high neutralizing antibody levels and protects from experimental chal	53
The impact of Facebook’s vaccine misinformation policy on user endorsements of vaccine content: An interrupted time series analysis	53